BioSpace News Archive

Eyecarrot Announces Shipment of its First 50 Binovi Touch Saccadic Fixator Units

After extensive development work, the release of the first 50 units represents a major milestone for the company

May 23, 2018

·

4 min read

Biotech Bay

RenovoRx Announces $10 Million Financing for Innovative Treatment for Advanced Pancreatic Cancer

Company’s RenovoCath System Has Received Orphan Drug Designation from the FDA for its Innovative Approach

May 23, 2018

·

3 min read

FDA

Synedgen Receives FDA 510(k) Clearance for Catasyn™ Advanced Technology Wound Hydrogel

FDA clearance for Catasyn provides patients with a new option to treat both minor burns and skin lacerations and physicians with an alternative to treat more severe dermal ulcers, post-operative incision sites and second degree burns.

May 23, 2018

·

3 min read

Business

Astero Bio Acquires Key Technologies for the Management of Cryopreserved Biologics from BroadOak Capital Partners

In conjunction with the acquisition, Astero will receive growth capital investment from BroadOak.

May 23, 2018

·

3 min read

Drug Development

Prota/MCRI Completes Enrolment of Phase 2b Multicentre Clinical Trial of Probiotic Oral Immunotherapy for the Treatment of Peanut Allergy (PPOIT-003)

200 patients have been enrolled and commenced on treatment The multicentre study is being conducted in Melbourne, Adelaide and Perth Treatment will continue through 2019 with top line results expected in the first quarter of 2020

May 23, 2018

·

3 min read

Business

Clinigen and Mitsubishi Tanabe initiate European Managed Access Program for edaravone to treat ALS

Clinigen Group plc has partnered with Mitsubishi Tanabe Pharma Corporation (‘MTPC’), to initiate a Managed Access Program (also known as an Early Access Program) in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (‘ALS’).

May 23, 2018

·

2 min read

BioMidwest

Kraig Biocraft Laboratories Develops New Breakthrough Spider Silk DNA Synthesis Protocols Accelerating Time to Market for New Products

Kraig Labs’ R&D team raises the bar in transgenic research.

May 23, 2018

·

3 min read

Drug Development

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment for Squamous Non-Small Cell Lung Cancer (NSCLC) in Pivotal Phase 3 KEYNOTE-407 Trial

KEYTRUDA Has Now Demonstrated an Improved Survival Benefit in Advanced NSCLC in Five Phase 3 Trials

May 23, 2018

·

25 min read

Business

mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States

The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment.

May 23, 2018

·

3 min read

Pharm Country

PAVmed Updates Expected Key Dates for Previously Announced Rights Offering

Company had filed a preliminary prospectus as part of a registration statement on Form S-1 with the Securities and Exchange Commission for a rights offering to stockholders of record on Monday, May 21, 2018.

May 23, 2018

·

3 min read